M8 Pharmaceuticals

Privately held: no public share price · Mexico

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
viloxazine(Qelbree)
Approved
norepinephrine transporterSmall molecule
Attention Deficit Hyperactivity Disorder

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
viloxazine · QelbreePhase 3Attention-Deficit/Hyperactivity Disorder
Est. primary completion 2026-12 · NCT02736656 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.